References
- Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med. 1931;54:437–47. doi:https://doi.org/10.1084/jem.54.3.437.
- Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun. 1999;67:6375–84. doi:https://doi.org/10.1128/IAI.67.12.6375-6384.1999.
- American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization of infants and children 2 months of age and older: update. Pediatrics. 1991;88:169–72.
- Madore DV, Johnson CL, Phipps DC, Popejoy LA, Eby R, Smith DH. Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1- to 6-month-old infants. Pediatrics. 1990;85:331–37.
- Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig A, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41. doi:https://doi.org/10.1086/648593.
- Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (London, England). 2006;368:1495–502. doi:https://doi.org/10.1016/S0140-6736(06)69637-2.
- Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Herva E, Takala A, Käyhty H, Karma P, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–09. doi:https://doi.org/10.1056/NEJM200102083440602.
- Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810–15. doi:https://doi.org/10.1097/00006454-200209000-00005.
- Esposito S, Principi N. Pneumococcal vaccines and the prevention of community-acquired pneumonia. Pulm Pharmacol Ther. 2015;32:124–29. doi:https://doi.org/10.1016/j.pupt.2014.02.003.
- O’Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, Whitney C, Santosham M. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211–20. doi:https://doi.org/10.1086/521833.
- Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006;5:651–67. doi:https://doi.org/10.1586/14760584.5.5.651.
- Papadatou I, Piperi C, Alexandraki K, Kattamis A, Theodoridou M, Spoulou V. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2014;59:862–65. doi:https://doi.org/10.1093/cid/ciu409.
- Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165(Suppl):S49–52. doi:https://doi.org/10.1093/infdis/165-supplement_1-s49.
- WHO Publication. Pneumococcal vaccines WHO position paper – 2012 – recommendations. Vaccine. 2012;30:4717–18. doi:https://doi.org/10.1016/j.vaccine.2012.04.093.
- Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O’Brien KL, Whitney CG. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33(Suppl 2):S109–18. doi:https://doi.org/10.1097/INF.0000000000000078.
- Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192–203. doi:https://doi.org/10.1016/j.vaccine.2010.04.008.
- Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017–26. doi:https://doi.org/10.1128/CVI.00062-10.
- van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, van Gaans-van den Brink JAM, Kuipers B, Knol MJ, Berbers GAM, Sanders EAM, Rots NY, van Els CA. Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2015;61:342–49. doi:https://doi.org/10.1093/cid/civ274.
- Casey JR, Block S, Puthoor P, Hedrick J, Almudevar A, Pichichero ME. A simple scoring system to improve clinical assessment of acute otitis media. Clin Pediatr (Phila). 2011;50:623–29. doi:https://doi.org/10.1177/0009922811398391.
- Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304–09. doi:https://doi.org/10.1097/INF.0b013e3181c1bc48.
- Kaur R, Adlowitz DG, Casey JR, Zeng M, Pichichero ME. Simultaneous assay for four bacterial species including Alloiococcus otitidis using multiplex-PCR in children with culture negative acute otitis media. Pediatr Infect Dis J. 2010;29:741–45. doi:https://doi.org/10.1097/INF.0b013e3181d9e639.
- Kaur R, Casey JR, Pichichero ME. Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children. Vaccine. 2011;29:1023–28. doi:https://doi.org/10.1016/j.vaccine.2010.11.055.
- Khaskhely N, Mosakowski J, Thompson RS, Khuder S, Smithson SL, Westerink MAJ. Phenotypic analysis of pneumococcal polysaccharide-specific B cells. J Immunol. 2012;188:2455–63. doi:https://doi.org/10.4049/jimmunol.1102809.
- Pichichero ME, Casey JR, Almudevar A, Basha S, Surendran N, Kaur R, Morris M, Livingstone AM, Mosmann TR. Functional immune cell differences associated with low vaccine responses in infants. J Infect Dis. 2016;213:2014–19. doi:https://doi.org/10.1093/infdis/jiw053.
- Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356–60. doi:https://doi.org/10.1128/CVI.13.3.356-360.2006.
- Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266–72. doi:https://doi.org/10.1128/CDLI.8.2.266-272.2001.
- Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514–19. doi:https://doi.org/10.1128/cdli.10.4.514-519.2003.
- Pichichero ME. Ten-year study of acute otitis media in Rochester, NY. Pediatr Infect Dis J. 2016;35:1027–32. doi:https://doi.org/10.1097/INF.0000000000001216.
- Sharma SK, Casey JR, Pichichero ME. Reduced serum IgG responses to pneumococcal antigens in otitis-prone children may be due to poor memory B-cell generation. J Infect Dis. 2012;205:1225–29. doi:https://doi.org/10.1093/infdis/jis179.
- Pichichero ME, Casey JR, Almudevar A. Nonprotective responses to pediatric vaccines occur in children who are otitis prone. Pediatr Infect Dis J. 2013;32:1163–68. doi:https://doi.org/10.1097/INF.0b013e31829e887e.
- Shi Y, Agematsu K, Ochs HD, Sugane K. Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol. 2003;108:128–37. doi:https://doi.org/10.1016/s1521-6616(03)00092-5.
- Basha S, Kaur R, Mosmann TR, Pichichero ME. Reduced T-helper 17 responses to Streptococcus pneumoniae in infection-prone children can be rescued by addition of innate cytokines. J Infect Dis. 2017;215:1321–30. doi:https://doi.org/10.1093/infdis/jix090.
- Waldrop SL, Davis KA, Maino VC, Picker LJ. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol. 1998;161:5284–95.
- Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol. 2009;21:298–304. doi:https://doi.org/10.1016/j.coi.2009.05.019.